araag2/HINT huggingface dataset:
Clinical trial NCT01274000 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: ym060, placebo
SMILES: CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients meeting the Rome III Diagnostic Criteria

          -  Loose (mushy) or watery stools within the last 3 months

          -  Abdominal discomfort and/or pain during their non-menstrual period

        Exclusion Criteria:

          -  Patients with a history of surgical resection of the stomach, small intestine or large
             intestine

          -  Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's
             disease or colitis ulcerative)

          -  Patients with a history or current diagnosis of colitis ischemic

          -  Patients with a current diagnosis of enteritis infectious

          -  Patients with a current diagnosis of hyperthyroidism or hypothyroidism

          -  Patients who are currently participating in another clinical trial (including a
             post-marketing clinical study) or those who participated in another clinical trial
             (including a post-marketing clinical study) within 12 weeks before the study

          -  Patients with a history or current diagnosis of malignant tumor

          -  Patients with a history of abuse of drugs or alcohol within 1 year or those who are
             currently abusing them
Clinical trial NCT01096732 (phase 2, status: terminated)
Conditions: pancreatic ductal adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: gdc-0449
SMILES: CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented tissue diagnosis of pancreatic ductal adenocarcinoma with a sufficient
             amount of tissue for Laser Capture Micro-dissection (LCM) of the stromal and tumour
             compartments.

          -  Confirmed eligibility for a Whipple's or distal pancreatectomy procedure by
             Multi-Disciplinary Team (MDT) and surgeon review.

          -  Adequate organ function defined as:

               -  Creatinine clearance ≥ 50ml/min (as defined by Cockcroft-Gault)

               -  Electrolytes (Sodium (Na)/Potassium (K)/Calcium (Ca)) within institutional normal
                  limits

               -  Alanine transaminase (ALT)/Aspartate transaminase (AST) <5*ULN

               -  Partial thromboplastin time (PTT)<2*ULN, prior supplementation with vitamin K is
                  allowed

               -  Adequate blood counts: neutrophils >1,500/μl, Hb > 6mmol/L,platelets >100.000/μl

               -  Albumin ≥ 25mg/dL

          -  Written informed consent

          -  Male or female aged 18 years or over.

          -  World Health Organization (WHO) performance status 0-1

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

          -  Males should not donate sperm during treatment or up to 3 months after the last dose.

          -  Women of childbearing potential are required to have a negative serum pregnancy test
             (with sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior
             to the first dose of GDC-0449.

        Exclusion Criteria:

          -  Known Hepatitis B/C or Human Immunodeficiency Virus (HIV) infection

          -  Known hypersensitivity to GDC-0449

          -  Active cardiac ischemic disease (this criterion only applies for participation in the
             imaging part of the study)

          -  Women, who are pregnant plan to become pregnant or are lactating (during the study or
             for up to 12 months after the last dose).

          -  Concurrent participation in another clinical trial using an investigational medicinal
             product.

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or in the judgment of the investigator would make it undesirable
             for the patient to enter the trial (i.e. patients is not able to swallow tablets).
Clinical trial NCT01177410 (phase 2, status: completed)
Conditions: irritable bowel syndrome with diarrhea
ICD codes: K58.0, K58.9
Drugs: placebo, mesalamine granules 750 mg, mesalamine granules 1500 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

        Male or non-pregnant, non-lactating female subjects Diagnosed with IBS confirmed by the
        Rome III criteria

        Meet the following IBS symptom scores in all categories during the diary eligibility
        period:

          -  An average daily score of greater than or equal to 3 for abdominal pain

          -  An average daily score of greater than or equal to 3 for bloating

          -  An average daily score of 5 or greater for stool consistency using the Bristol Stool
             Scale

          -  Does not have adequate relief of IBS symptoms (weekly reported) over the past 7 days
             on the first day of screening and on the day of randomization

        Exclusion Criteria:

          -  Present with hard or lumpy stools (Type 1 or Type 2) on the Bristol Stool form Scale
             during the diary eligibility period

          -  history of inflammatory bowel disease

          -  has Type 1 or 2 diabetes

          -  pregnant or lactating

          -  history of HIV or hepatitis B or C
Clinical trial NCT00436800 (phase 2, status: completed)
Conditions: nasopharyngeal neoplasms
ICD codes: A36.1, B87.3
Drugs: gemcitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically or cytologically proven nasopharyngeal carcinoma (NPC)
             with metastatic or recurrent disease that is not amenable to potentially curative
             surgery or radiotherapy. They must not have prior chemotherapy for the treatment of
             metastatic or recurrent disease.

          -  Prior neoadjuvant, adjuvant or concurrent chemotherapy is allowed as long as a minimum
             period of 6 weeks has elapsed since the last day of treatment. This includes the use
             of carboplatin or cisplatin.

          -  Patients must have at least one uni-dimensional measurable lesion (according to RECIST
             criteria)

          -  Prior RT or surgery to the target lesion(s) is allowed as long as there is documented
             disease progression within the RT/ surgical field, and a minimum period of 6 weeks has
             elapsed since the last day of treatment.

          -  Eastern Cooperative Oncology Group performance status of 0-2

          -  No serious, uncontrolled medical conditions that may be aggravated by treatment.

          -  No other malignancy(s), except completely excised basal or squamous cell carcinoma of
             the skin, or completely treated carcinoma-in-situ of the cervix.

          -  Adequate hematological function:absolute granulocyte count > 1.5 x 10^9/L, platelet
             count > 100 x 10^9/L

          -  Adequate renal and hepatic functions:·serum creatinine < 1.25 x upper normal limit
             (UNL) or a calculated creatinine clearance > 50 mL/min·serum bilirubin < 2 x UNL and
             Aspartate aminotransferase/Alanine aminotransferase < 3 x UNL

        Exclusion Criteria:

          -  Prior treatment with Oxaliplatin or Gemcitabine.

          -  Patients who have persistent grade 2 or more sensory and/or motor neuropathy, or
             ototoxicity resulting from prior cisplatin/ carboplatin.

          -  Active or past history of central nervous system metastasis from the primary tumor

          -  Potentially life-threatening infections

          -  Patients have used any investigational drug treatment in the month prior to inclusion.

          -  Pregnancy or not exercising appropriate birth control during the course of the study.
             Breast-feeding women

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00689585 (phase 2, status: terminated)
Conditions: complex regional pain syndromes
ICD codes: G90.50, G90.511, G90.512, G90.513, G90.519, G90.521, G90.522
Drugs: placebo, ethosuximide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC1(C)CC(=O)NC1=O
Reason stopped: 
    recruitment difficult and enrolment low: decision was made to stop the study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age ≥18 years old;

          -  Diagnosis of Complex Regional Pain Syndrome (CRPS) using International Association for
             the Study of Pain criteria >6 months;

          -  Normal liver function (AST level <3x normal level);

          -  Normal kidney function (serum creatinine <133µmol/L);

          -  Full blood count, haematocrit >38%;

          -  Willing and able to give informed consent and of completing study questionnaires;

          -  Stable (no change in past two months) but suboptimal pain pharmacotherapy (i.e.
             additional pain control felt by patient and physician to be necessary);

          -  Able to attend research centre according to the visit schedule;

          -  Women of child-bearing potential must be using a reliable form of contraception i.e.
             oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or
             abstinence.

        Exclusion Criteria:

          -  Optimal response to opioids, antidepressants, anticonvulsants or anti- inflammatory
             medications;

          -  Any history or indication of kidney or liver disease;

          -  Any history of alcohol abuse;

          -  Presence of diabetes;

          -  Subjects taking other anti-epileptic drugs, including gabapentin, pregabalin,
             topiramate, phenytoin, carbamazepine, and oxcarbazepine;

          -  Pregnancy (a serum bHCG pregnancy test will be performed as part of the initial blood
             panel);

          -  Known or suspected allergy to succinimides, ethosuximide, methsuximide (Celontin®),
             phensuximide;

          -  Any history of mental illness or disorder, which in the investigators opinion,
             interferes with the subjects ability to accurately report treatment response;

          -  Participation in other clinical trial in the 30 days prior to enrolment.
Clinical trial NCT02585869 (phase 2, status: completed)
Conditions: hypercholesterolemia, hypertriglyceridemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: gemcabene 150 mg, gemcabene 300 mg, gemcabene 600 mg, gemcabene 900 mg, placebo
SMILES: CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or naturally postmenopausal or surgically menopausal women

          -  18 to 80 years of age

          -  Baseline HDL-C <35 mg/dL (0.9 mmol/L)

        Exclusion Criteria:

          -  Creatine phosphokinase (CPK) >3 × the upper limit of normal (ULN)

          -  Body Mass Index (BMI) >35 kg/m2

          -  Uncontrolled Hypertension >95 mm Hg

          -  Uncontrolled diabetes mellitus (HbA1c >10%)

          -  Renal dysfunction (blood urea nitrogen [BUN] or creatinine >2 × ULN);

          -  Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase
             [ALT] >2 × ULN)

          -  Uncontrolled hypothyroidism (TSH >1.5 × ULN)

          -  Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty,
             coronary artery bypass graft, or any other major cardiovascular event resulting in
             hospitalization in previous 3 months
Clinical trial NCT00309608 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: linagliptin, linagliptin, linagliptin, placebo, glimepiride
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion criteria:

        Inclusion_Criteria:

          -  Male and female patients with a diagnosis of type 2 diabetes mellitus and previo usly
             treated with metformin alone or with metformin and one other oral antidiabetic d rug

          -  HbA1c 7.0 9.0% at screening for patients treated with metformin and one other oral
             antidiabetic drug

          -  HbA1c 7.5 10.0% at screening for patients treated with metformin alone

          -  HbA1c 7.5 10.0% at beginning of the placebo run-in phase

          -  Age > 21 and < 75 years

          -  MI > 25 and < 40 kg/m2 (Body Mass Index)

        Exclusion criteria:

        Exclusion_Criteria:

          -  Clinically relevant cardiovascular disease

          -  Impaired hepatic function

          -  Renal insufficiency or impaired renal function

          -  Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

          -  Treatment with insulin within 3 months prior to screening
Clinical trial NCT00104429 (phase 2, status: terminated)
Conditions: infection, human immunodeficiency virus i, hiv infection
ICD codes: Z21, Z21
Drugs: gw873140, combivir
SMILES: [H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1, [H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1
Eligibility criteria:

        Inclusion criteria:

          -  HIV infected subjects.

          -  Females must be of either non-childbearing age, or have a negative pregnancy test.

          -  All subjects participating in this study should be counseled on the practice of safe
             sex using a proven double barrier method of contraception throughout the study.

          -  Screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and
             CD4 cell count greater than or equal to 100 cells/mm3.

          -  Have CC Chemokine Receptor5-tropic (R5-tropic) virus based on viral tropism test at
             screening visit.

          -  Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance
             test at screening visit.

          -  Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a
             protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide
             reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of
             therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).

          -  Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor
             (experimental or approved) is not allowed.

          -  Be able to understand and follow with protocol requirements, instructions and
             protocol-stated restrictions.

          -  Signed and dated written informed consent prior to study entry.

        Exclusion criteria:

          -  Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test
             at screening.

          -  Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test
             at screening visit.

          -  Active Class C AIDS-defining illness.

          -  Laboratory abnormalities at screen.

          -  Significant blood loss prior to study start.

          -  Pregnant or breastfeeding women.

          -  Additional qualifying criteria to be determined by the physician.
Clinical trial NCT00678288 (phase 2, status: terminated)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib (nexavar, bay43-9006), sorafenib (nexavar, bay43-9006) + interferon
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Disease progression as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria following documented stable disease or better after at least 8 weeks
             of sunitinib as first-line treatment (or two cycles of 4 weeks on and 2 weeks off
             treatment)

          -  And/or patients who have discontinued sunitinib treatment at any point due to toxicity

          -  Study entry at least 2 weeks after treatment with sunitinib but up to a maximum of 8
             weeks

          -  Memorial Sloane Kettering Cancer Centre (MSKCC) prognostic score low or intermediate

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Patient must have histologically confirmed metastatic renal cell carcinoma with
             predominant clear cell histology (clear cell component more than 50%).

        Exclusion Criteria:

          -  Patient should be excluded if they have unresolved chronic toxicity grade

          -  > 1 and related to prior therapy with sunitinib.
Clinical trial NCT01288469 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, placebo (for alirocumab), atorvastatin, placebo (for atorvastatin)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        - Participants receiving a lipid-lowering treatment other than atorvastatin/ or not at
        stable dose of atorvastatin 10 mg for at least 6 weeks prior to screening, or drug naive
        participants with primary hypercholesterolemia if they are likely to have low-density
        lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in
        treatment period on atorvastatin therapy

        OR

        - Participants with primary hypercholesterolemia treated with stable dose of atorvastatin
        10 mg for at least 6 weeks prior to screening and likely to have low-density lipoprotein
        cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit.

        Exclusion criteria:

          1. LDL-C < 100 mg/dL (< 2.59 mmol/L) at Week -1 (V1):

               -  After the run-in period on atorvastatin 10 mg for participants receiving a lipid
                  lowering treatment other than atorvastatin/ or not at stable dose of atorvastatin
                  10 mg for at least 6 weeks prior to the screening period, or drug naive
                  participants.

             OR

               -  At the first visit for participants who are being treated with atorvastatin 10 mg
                  at stable dose for at least 6 weeks prior to screening visit.

          2. Participants not previously instructed on a cholesterol-lowering diet.

          3. Participants with type 1 diabetes.

          4. Participants with type 2 diabetes treated with insulin.

          5. Participants with type 2 diabetes and with an HbA1c ≥ 8.5% at screening visit
             (considered poorly controlled).

          6. Laboratory findings measured before randomization:

               -  Triglycerides (TG) > 350 mg/dL (> 3.95 mmol/L) at screening visit.

               -  Positive serum or urine pregnancy test in females of childbearing potential.

          7. Pregnant or breast-feeding women.

          8. Women of childbearing potential with no effective contraceptive method.

        The above information is not intended to contain all considerations relevant to a
        Participant's potential participation in a clinical trial.
Clinical trial NCT00659490 (phase 2, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: azd1940, naproxen, placebo
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled for surgical removal of one partial or complete impacted mandibular
             third molar.

          -  Provision of signed informed consent.

          -  Healthy males or non-fertile females.

        Exclusion Criteria:

          -  History of somatic disease/condition, which may interfere with the objectives of the
             study, as judged by the investigator.

          -  History of previous or ongoing psychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, borderline state and personality disorder
             according to the criteria in the Diagnostic and Statistical Manual of Mental Disorder,
             4th edition.
Clinical trial NCT01710345 (phase 2, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: sufentanil nanotab 20 mcg, sufentanil nanotab 30 mcg, placebo nanotab
SMILES: CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1, CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients scheduled for bunion surgery

        Exclusion Criteria:

          -  daily opioid use

          -  drug or alcohol abuse

          -  pregnant or breastfeeding women
Clinical trial NCT01550055 (phase 2/phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cmab009 plus irinotecan, irinotecan-only and sequential-cmab009
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  histologically confirmed metastatic colorectal adenocarcinoma

          -  KRAS wild-type tumors, EGFR-expressing or EGFR-nonexpressing by immunohistochemistry;

          -  has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diametre by
             physical examination or other iconography

          -  ECOG performance status 0 to 1

          -  Failure (disease progression/discontinuation due to toxicity) of fluoropyrimidine and
             oxaliplatin treatment,stop at least one month thereafter, irinotecan-naïve

        Exclusion Criteria:

          -  Previous irinotecan or anti-EGFR therapies

          -  hematologic function: hemoglobin, less than 90g per liter; neutrophil count, less than
             1500 per cubic millimeter; and platelet count, less than 100,000 per cubic millimeter

          -  liver function: bilirubin, more than 1.0 times the upper limit of normal; aspartate
             aminotransferase and alanine aminotransferase, more than 5.0 times and 2.5 times the
             upper limit of normal with hepatic metastasis or not

          -  Renal function: serum creatinine, more than 1.5 times the upper limit of normal

          -  Patients with symptomatic central nervous system metastases